HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)

Massimo Pilli, Alessandro Zerbini, Amalia Penna, Alessandra Orlandini, Esther Lukasiewicz, Jean Michel Pawlotsky, Stefan Zeuzem, Solko W. Schalm, Michael von Wagner, Georgios Germanidis, Yoav Lurie, Juan I. Esteban, Bart L. Haagmans, Christophe Hezode, Martin Lagging, Francesco Negro, Yonit Homburger, Avidan U. Neumann, Carlo Ferrari, Gabriele Missale

Research output: Contribution to journalArticle

Abstract

Background & Aims: The second slope of viral decline induced by interferon treatment has been suggested to be influenced mainly by the hepatitis C virus (HCV)-specific T-cell response; however, this hypothesis needs to be validated by results derived from experimental studies. Methods: To address this issue, the HCV-specific T-cell response of 32 genotype-1-infected patients of the 270 patients enrolled in the dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics phase III, open-label, randomized, multicenter trial was studied in relation to viral kinetics and treatment outcome. Results: Greater proliferative responses by HCV-specific CD8 cells were found before treatment in patients with a fast viral decline and with a sustained viral response. However, no significant improvement of HCV-specific CD8 responses was observed in the first weeks of therapy in both rapid viral responder and non-rapid viral responder patients. A mild enhancement of proliferative T-cell responses and a partial restoration of the cytotoxic T-cell potential was expressed only late during treatment, likely favored by HCV clearance. Conclusions: Early restoration of an efficient T-cell response does not seem to be an essential requirement for a rapid viral decline in the first weeks of treatment. However, patients presenting a better HCV-specific CD8 cell proliferative potential at baseline are more likely to present a rapid and sustained viral response. Therefore, future treatment protocols should consider the development of strategies aimed at improving HCV-specific T-cell responses.

Original languageEnglish
Pages (from-to)1132-1143
Number of pages12
JournalGastroenterology
Volume133
Issue number4
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Hepacivirus
T-Lymphocytes
Therapeutics
Virus Diseases
Hepatitis C
Clinical Protocols
Interferons
Multicenter Studies
Genotype

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pilli, M., Zerbini, A., Penna, A., Orlandini, A., Lukasiewicz, E., Pawlotsky, J. M., ... Missale, G. (2007). HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 133(4), 1132-1143. https://doi.org/10.1053/j.gastro.2007.06.059

HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). / Pilli, Massimo; Zerbini, Alessandro; Penna, Amalia; Orlandini, Alessandra; Lukasiewicz, Esther; Pawlotsky, Jean Michel; Zeuzem, Stefan; Schalm, Solko W.; von Wagner, Michael; Germanidis, Georgios; Lurie, Yoav; Esteban, Juan I.; Haagmans, Bart L.; Hezode, Christophe; Lagging, Martin; Negro, Francesco; Homburger, Yonit; Neumann, Avidan U.; Ferrari, Carlo; Missale, Gabriele.

In: Gastroenterology, Vol. 133, No. 4, 10.2007, p. 1132-1143.

Research output: Contribution to journalArticle

Pilli, M, Zerbini, A, Penna, A, Orlandini, A, Lukasiewicz, E, Pawlotsky, JM, Zeuzem, S, Schalm, SW, von Wagner, M, Germanidis, G, Lurie, Y, Esteban, JI, Haagmans, BL, Hezode, C, Lagging, M, Negro, F, Homburger, Y, Neumann, AU, Ferrari, C & Missale, G 2007, 'HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)', Gastroenterology, vol. 133, no. 4, pp. 1132-1143. https://doi.org/10.1053/j.gastro.2007.06.059
Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM et al. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology. 2007 Oct;133(4):1132-1143. https://doi.org/10.1053/j.gastro.2007.06.059
Pilli, Massimo ; Zerbini, Alessandro ; Penna, Amalia ; Orlandini, Alessandra ; Lukasiewicz, Esther ; Pawlotsky, Jean Michel ; Zeuzem, Stefan ; Schalm, Solko W. ; von Wagner, Michael ; Germanidis, Georgios ; Lurie, Yoav ; Esteban, Juan I. ; Haagmans, Bart L. ; Hezode, Christophe ; Lagging, Martin ; Negro, Francesco ; Homburger, Yonit ; Neumann, Avidan U. ; Ferrari, Carlo ; Missale, Gabriele. / HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). In: Gastroenterology. 2007 ; Vol. 133, No. 4. pp. 1132-1143.
@article{2dbc4ff2be804ae795cff9e97815ff3a,
title = "HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)",
abstract = "Background & Aims: The second slope of viral decline induced by interferon treatment has been suggested to be influenced mainly by the hepatitis C virus (HCV)-specific T-cell response; however, this hypothesis needs to be validated by results derived from experimental studies. Methods: To address this issue, the HCV-specific T-cell response of 32 genotype-1-infected patients of the 270 patients enrolled in the dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics phase III, open-label, randomized, multicenter trial was studied in relation to viral kinetics and treatment outcome. Results: Greater proliferative responses by HCV-specific CD8 cells were found before treatment in patients with a fast viral decline and with a sustained viral response. However, no significant improvement of HCV-specific CD8 responses was observed in the first weeks of therapy in both rapid viral responder and non-rapid viral responder patients. A mild enhancement of proliferative T-cell responses and a partial restoration of the cytotoxic T-cell potential was expressed only late during treatment, likely favored by HCV clearance. Conclusions: Early restoration of an efficient T-cell response does not seem to be an essential requirement for a rapid viral decline in the first weeks of treatment. However, patients presenting a better HCV-specific CD8 cell proliferative potential at baseline are more likely to present a rapid and sustained viral response. Therefore, future treatment protocols should consider the development of strategies aimed at improving HCV-specific T-cell responses.",
author = "Massimo Pilli and Alessandro Zerbini and Amalia Penna and Alessandra Orlandini and Esther Lukasiewicz and Pawlotsky, {Jean Michel} and Stefan Zeuzem and Schalm, {Solko W.} and {von Wagner}, Michael and Georgios Germanidis and Yoav Lurie and Esteban, {Juan I.} and Haagmans, {Bart L.} and Christophe Hezode and Martin Lagging and Francesco Negro and Yonit Homburger and Neumann, {Avidan U.} and Carlo Ferrari and Gabriele Missale",
year = "2007",
month = "10",
doi = "10.1053/j.gastro.2007.06.059",
language = "English",
volume = "133",
pages = "1132--1143",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)

AU - Pilli, Massimo

AU - Zerbini, Alessandro

AU - Penna, Amalia

AU - Orlandini, Alessandra

AU - Lukasiewicz, Esther

AU - Pawlotsky, Jean Michel

AU - Zeuzem, Stefan

AU - Schalm, Solko W.

AU - von Wagner, Michael

AU - Germanidis, Georgios

AU - Lurie, Yoav

AU - Esteban, Juan I.

AU - Haagmans, Bart L.

AU - Hezode, Christophe

AU - Lagging, Martin

AU - Negro, Francesco

AU - Homburger, Yonit

AU - Neumann, Avidan U.

AU - Ferrari, Carlo

AU - Missale, Gabriele

PY - 2007/10

Y1 - 2007/10

N2 - Background & Aims: The second slope of viral decline induced by interferon treatment has been suggested to be influenced mainly by the hepatitis C virus (HCV)-specific T-cell response; however, this hypothesis needs to be validated by results derived from experimental studies. Methods: To address this issue, the HCV-specific T-cell response of 32 genotype-1-infected patients of the 270 patients enrolled in the dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics phase III, open-label, randomized, multicenter trial was studied in relation to viral kinetics and treatment outcome. Results: Greater proliferative responses by HCV-specific CD8 cells were found before treatment in patients with a fast viral decline and with a sustained viral response. However, no significant improvement of HCV-specific CD8 responses was observed in the first weeks of therapy in both rapid viral responder and non-rapid viral responder patients. A mild enhancement of proliferative T-cell responses and a partial restoration of the cytotoxic T-cell potential was expressed only late during treatment, likely favored by HCV clearance. Conclusions: Early restoration of an efficient T-cell response does not seem to be an essential requirement for a rapid viral decline in the first weeks of treatment. However, patients presenting a better HCV-specific CD8 cell proliferative potential at baseline are more likely to present a rapid and sustained viral response. Therefore, future treatment protocols should consider the development of strategies aimed at improving HCV-specific T-cell responses.

AB - Background & Aims: The second slope of viral decline induced by interferon treatment has been suggested to be influenced mainly by the hepatitis C virus (HCV)-specific T-cell response; however, this hypothesis needs to be validated by results derived from experimental studies. Methods: To address this issue, the HCV-specific T-cell response of 32 genotype-1-infected patients of the 270 patients enrolled in the dynamically individualized treatment of hepatitis C infection and correlates of viral/host dynamics phase III, open-label, randomized, multicenter trial was studied in relation to viral kinetics and treatment outcome. Results: Greater proliferative responses by HCV-specific CD8 cells were found before treatment in patients with a fast viral decline and with a sustained viral response. However, no significant improvement of HCV-specific CD8 responses was observed in the first weeks of therapy in both rapid viral responder and non-rapid viral responder patients. A mild enhancement of proliferative T-cell responses and a partial restoration of the cytotoxic T-cell potential was expressed only late during treatment, likely favored by HCV clearance. Conclusions: Early restoration of an efficient T-cell response does not seem to be an essential requirement for a rapid viral decline in the first weeks of treatment. However, patients presenting a better HCV-specific CD8 cell proliferative potential at baseline are more likely to present a rapid and sustained viral response. Therefore, future treatment protocols should consider the development of strategies aimed at improving HCV-specific T-cell responses.

UR - http://www.scopus.com/inward/record.url?scp=34848870230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848870230&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2007.06.059

DO - 10.1053/j.gastro.2007.06.059

M3 - Article

C2 - 17919489

AN - SCOPUS:34848870230

VL - 133

SP - 1132

EP - 1143

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -